275 related articles for article (PubMed ID: 36049604)
1. The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review.
Levinta A; Meshkat S; McIntyre RS; Ho C; Lui LMW; Lee Y; Mansur RB; Teopiz KM; Rodrigues NB; Di Vincenzo JD; Ceban F; Rosenblat JD
J Affect Disord; 2022 Dec; 318():139-149. PubMed ID: 36049604
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.
Calder CN; Kwan ATH; Teopiz KM; Wong S; Rosenblat JD; Mansur RB; Rhee TG; Ho R; Cao B; McIntyre RS
J Affect Disord; 2024 Jul; 356():753-762. PubMed ID: 38636712
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
Seshadri A; Prokop LJ; Singh B
J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
[TBL] [Abstract][Full Text] [Related]
6. Ketamine and other glutamate receptor modulators for depression in adults.
Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
[TBL] [Abstract][Full Text] [Related]
7. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; van Asselt ADI; Touw DJ; Aan Het Rot M; Schoevers RA
BMC Psychiatry; 2019 Nov; 19(1):375. PubMed ID: 31783823
[TBL] [Abstract][Full Text] [Related]
8. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
9. Esketamine for treatment resistant depression.
Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
[No Abstract] [Full Text] [Related]
10. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
[TBL] [Abstract][Full Text] [Related]
11. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
[TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
Caliman-Fontes AT; Leal GC; Correia-Melo FS; Paixão CS; Carvalho MS; Jesus-Nunes AP; Vieira F; Magnavita G; Bandeira ID; Mello RP; Beanes G; Silva SS; Echegaray M; Carvalho LP; Machado P; Sampaio AS; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC
Trends Psychiatry Psychother; 2023; 45():e20210298. PubMed ID: 34904800
[TBL] [Abstract][Full Text] [Related]
13. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
[TBL] [Abstract][Full Text] [Related]
14. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
15. Increased use of ketamine for the treatment of depression: Benefits and concerns.
Na KS; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110060. PubMed ID: 32777326
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.
Alnefeesi Y; Chen-Li D; Krane E; Jawad MY; Rodrigues NB; Ceban F; Di Vincenzo JD; Meshkat S; Ho RCM; Gill H; Teopiz KM; Cao B; Lee Y; McIntyre RS; Rosenblat JD
J Psychiatr Res; 2022 Jul; 151():693-709. PubMed ID: 35688035
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review.
Kumar R; Nuñez NA; Joshi N; Joseph B; Verde A; Seshadri A; Cuellar Barboza AB; Prokop LJ; Medeiros GC; Singh B
Bipolar Disord; 2024 Jun; 26(4):321-330. PubMed ID: 38326104
[TBL] [Abstract][Full Text] [Related]
18. A historical review of antidepressant effects of ketamine and its enantiomers.
Wei Y; Chang L; Hashimoto K
Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
[TBL] [Abstract][Full Text] [Related]
19. Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
Beanes G; Caliman-Fontes AT; Souza-Marques B; Silva HDS; Leal GC; Carneiro BA; Guerreiro-Costa LNF; Figueiredo AV; Figueiredo CAV; Lacerda ALT; Costa RDS; Quarantini LC
Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):151-156. PubMed ID: 36093918
[TBL] [Abstract][Full Text] [Related]
20. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Singh JB; Fedgchin M; Daly EJ; Drevets WC
Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
